Louise Helander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Louise Helander has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Brian David Adkins
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Kyle Annen
Children's Hospital Colorado Aurora Colorado USA
2 shared publications - Lani Lieberman
Department of Clinical Pathology University Health Network Toronto Ontario Canada
2 shared publications - Benjamin A. Olsen
Department of Pediatrics, University of Colorado Graduate Medical Education, 13123 E. 16th Ave, Aurora, CO 80045
1 shared publication Brian Nguyen
Department of Pathology University of Colorado Anschutz Medical Campus Aurora Colorado USA
1 shared publicationCaroline Raasch Alquist
Hoxworth Blood Center, University of Cincinnati
1 shared publication
Latest Publications
- 27 August 2026
- Published by Wiley in Transfusion
Transfusion thresholds in apheresis: Results from a survey and focus group discussion
Background: Clinical practice guidelines for red blood cell (RBC) or platelet transfusion are not tailored specifically for therapeutic apheresis patients. It is unclear how provider transfusion thresholds in the peri‐therapeutic apheresis period correlate with guidelines. We hypothesized that individual apheresis clinician practice would not wholly adhere to transfusion guidelines. Study Design and Methods: A large, international survey was designed, beta tested, piloted and sent to all members of the Association for the Advancement of Blood & Biotherapies (AABB) Therapeutic Apheresis Subsection ( n = 459). Responses of interest were used to generate discussion points for an open, expert‐moderated focus group discussion at the 2024 AABB Annual Meeting. Results: Total survey response rate was 10%, n = 47. Calculated sample size (survey responses) for 95% confidence level with a 10% margin of error was n = 80. Nonetheless, responses of interest were generated, including some responses deemed discordant with international guidelines. Five topics were discussed by the focus groups: (1) platelet transfusion thresholds, (2) transfusion methods prior to central venous catheter placement, (3) therapeutic plasma exchange platelet repletion, (4) hemoglobin transfusion threshold prior to RBC exchange, and (5) platelet transfusion threshold for initiating therapeutic plateletpheresis. Conclusion: The survey results and focus group discussion, framed within current international guidelines and the literature, highlighted the need for enhancing the value of apheresis providers' clinical judgment and ability to impact institutional policies.
- 27 August 2026
- Published by Wiley in Transfusion
Transfusion thresholds in apheresis: Results from a survey and focus group discussion
Background: Clinical practice guidelines for red blood cell (RBC) or platelet transfusion are not tailored specifically for therapeutic apheresis patients. It is unclear how provider transfusion thresholds in the peri‐therapeutic apheresis period correlate with guidelines. We hypothesized that individual apheresis clinician practice would not wholly adhere to transfusion guidelines. Study Design and Methods: A large, international survey was designed, beta tested, piloted and sent to all members of the Association for the Advancement of Blood & Biotherapies (AABB) Therapeutic Apheresis Subsection ( n = 459). Responses of interest were used to generate discussion points for an open, expert‐moderated focus group discussion at the 2024 AABB Annual Meeting. Results: Total survey response rate was 10%, n = 47. Calculated sample size (survey responses) for 95% confidence level with a 10% margin of error was n = 80. Nonetheless, responses of interest were generated, including some responses deemed discordant with international guidelines. Five topics were discussed by the focus groups: (1) platelet transfusion thresholds, (2) transfusion methods prior to central venous catheter placement, (3) therapeutic plasma exchange platelet repletion, (4) hemoglobin transfusion threshold prior to RBC exchange, and (5) platelet transfusion threshold for initiating therapeutic plateletpheresis. Conclusion: The survey results and focus group discussion, framed within current international guidelines and the literature, highlighted the need for enhancing the value of apheresis providers' clinical judgment and ability to impact institutional policies.
- Open Access
- 28 June 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2233-2243
AABB survey on directed blood donation practices
Background: Standardized guidance regarding the processes for collecting directed blood donations (DBD) is lacking, leading to variable practices. This study assessed laboratory, clinical, and charging practices for DBD collection in the United States and Canada. Study Design and Methods: An electronic survey was distributed to United States and Canadian blood collection centers and hospitals to evaluate institutional demographics, policies, indications, medical oversight, and financial responsibility for DBD collection. Results: Survey respondents included 193 hospitals and 10 blood collection centers with a response rate of 34% (203/594). Red blood cells were the most commonly collected DBD product. Fifty percent (5/10) of blood center respondents did not include the rationale for the DBD request on requisitions. Non‐medical requests were accommodated by 70% (7/10) of blood centers and 42% (81/193) of hospitals. Transfusion Medicine review was not required by 48% (98/203). Safety practices also varied: only 60% (53/88) verify donor‐recipient ABO suitability prior to collection, and 57% (50/88) had no additional exclusion criteria for high‐risk related donors. Forty‐four percent of respondents reported additional charges, but many hospitals reported uncertainty about billing. Most hospitals (59%) reported wasting DBD units, with higher discard rates among those that do not return units to general inventory. Conclusion: Heterogeneous DBD practices reflect the absence of standard policies. Lack of oversight and safety checks may expose patients to unnecessary risks. The authors outline key considerations for DBD requests to standardize safeguards, including defined exclusion criteria for high‐risk donor‐recipient pairs and education on DBD risks.
- 28 June 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2233-2243
Open AccessAABB survey on directed blood donation practices
Background: Standardized guidance regarding the processes for collecting directed blood donations (DBD) is lacking, leading to variable practices. This study assessed laboratory, clinical, and charging practices for DBD collection in the United States and Canada. Study Design and Methods: An electronic survey was distributed to United States and Canadian blood collection centers and hospitals to evaluate institutional demographics, policies, indications, medical oversight, and financial responsibility for DBD collection. Results: Survey respondents included 193 hospitals and 10 blood collection centers with a response rate of 34% (203/594). Red blood cells were the most commonly collected DBD product. Fifty percent (5/10) of blood center respondents did not include the rationale for the DBD request on requisitions. Non‐medical requests were accommodated by 70% (7/10) of blood centers and 42% (81/193) of hospitals. Transfusion Medicine review was not required by 48% (98/203). Safety practices also varied: only 60% (53/88) verify donor‐recipient ABO suitability prior to collection, and 57% (50/88) had no additional exclusion criteria for high‐risk related donors. Forty‐four percent of respondents reported additional charges, but many hospitals reported uncertainty about billing. Most hospitals (59%) reported wasting DBD units, with higher discard rates among those that do not return units to general inventory. Conclusion: Heterogeneous DBD practices reflect the absence of standard policies. Lack of oversight and safety checks may expose patients to unnecessary risks. The authors outline key considerations for DBD requests to standardize safeguards, including defined exclusion criteria for high‐risk donor‐recipient pairs and education on DBD risks.
- 1 April 2026
- Published by Wiley in Transfusion
- Vol. 66 (5) , 901-902
An unusual case of short tandem repeat analysis with foreign peaks due to granulocyte transfusion
- 1 April 2026
- Published by Wiley in Transfusion
- Vol. 66 (5) , 901-902
An unusual case of short tandem repeat analysis with foreign peaks due to granulocyte transfusion
- Open Access
- 8 September 2024
- Published by Wiley in Transfusion
- Vol. 64 (10) , 1860-1869
Survey of pediatric massive transfusion protocol practice at United States level I trauma centers: An AABB Pediatric Transfusion Medicine Subsection study
Background: Trauma remains the leading cause of pediatric mortality in the United States. Although use of massive transfusion protocols (MTPs) in this population is widespread, optimal pediatric resuscitation is not well established. We sought to assess contemporary pediatric MTP practice in the United States.Study Design and Methods: A web‐based survey was designed by the Association for the Advancement of Blood & Biotherapies (AABB) Pediatric Transfusion Medicine Subsection and distributed to select American College of Surgeons (ACS) Level I Verified pediatric trauma centers. The survey assessed current MTP policy, implementation, and recent changes in practice.Results: Response rate was 55% (22/40). Almost half of the respondents were from the South. The median RBC:plasma ratio was 1 (interquartile range 1–1.5). Protocolized fibrinogen supplementation was common while integration of antifibrinolytic therapy into MTPs was infrequent. Viscoelastic testing (VET) was available at most sites, 71% (15/21, one site did not respond), and was generally utilized on an ad‐hoc basis. Roughly, a third of sites had changed their MTP in the past 3 years due to blood supply issues, and about a third reported having group O Whole Blood on‐site.Conclusion: MTP practice is similar throughout the United States. Though fibrinogen supplementation is common—other emerging interventions such as antifibrinolytic therapy or utilization of routine viscoelastic testing—are not widespread. Pediatric transfusion medicine experts must continue to follow practice change, as contemporary large trials begin to characterize new supportive modalities to optimize resuscitation in pediatric trauma patients.
- 8 September 2024
- Published by Wiley in Transfusion
- Vol. 64 (10) , 1860-1869
Open AccessSurvey of pediatric massive transfusion protocol practice at United States level I trauma centers: An AABB Pediatric Transfusion Medicine Subsection study
Background: Trauma remains the leading cause of pediatric mortality in the United States. Although use of massive transfusion protocols (MTPs) in this population is widespread, optimal pediatric resuscitation is not well established. We sought to assess contemporary pediatric MTP practice in the United States.Study Design and Methods: A web‐based survey was designed by the Association for the Advancement of Blood & Biotherapies (AABB) Pediatric Transfusion Medicine Subsection and distributed to select American College of Surgeons (ACS) Level I Verified pediatric trauma centers. The survey assessed current MTP policy, implementation, and recent changes in practice.Results: Response rate was 55% (22/40). Almost half of the respondents were from the South. The median RBC:plasma ratio was 1 (interquartile range 1–1.5). Protocolized fibrinogen supplementation was common while integration of antifibrinolytic therapy into MTPs was infrequent. Viscoelastic testing (VET) was available at most sites, 71% (15/21, one site did not respond), and was generally utilized on an ad‐hoc basis. Roughly, a third of sites had changed their MTP in the past 3 years due to blood supply issues, and about a third reported having group O Whole Blood on‐site.Conclusion: MTP practice is similar throughout the United States. Though fibrinogen supplementation is common—other emerging interventions such as antifibrinolytic therapy or utilization of routine viscoelastic testing—are not widespread. Pediatric transfusion medicine experts must continue to follow practice change, as contemporary large trials begin to characterize new supportive modalities to optimize resuscitation in pediatric trauma patients.
- Open Access
- 23 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 994321
Chronic granulomatous disease and McLeod syndrome: Stem cell transplant and transfusion support in a 2-year-old patient—a case report
Chronic granulomatous disease (CGD) with McLeod neuroacanthocytosis syndrome (MLS) is a contiguous gene deletion disorder characterized by defective phagocytic function and decreased Kell antigen expression. CGD cure is achieved through hematopoietic stem cell transplant (HSCT) usually in the peri-pubescent years. The presence of MLS makes peri-transfusion support complex, however. Herein, we present the youngest known case of HSCT for CGD in the setting of MLS. A 2-year-old male patient was diagnosed with CGD plus MLS. Due to the severity of the child’s systemic fungal infection at diagnosis, HSCT was deemed the best treatment option despite his small size and age. A related, matched donor was available, and a unique red blood cell support plan had been implemented. Reduced-intensity conditioning was used to reduce the transplant-related mortality risk associated with myeloablative protocols. The transplant course was uneventful; autologous red blood cell (RBC) transfusion support was successful and allowed for the avoidance of possible antibody formation if allogeneic units had been used. The patient achieved 1-year relapse-free survival. The developed protocols provide a viable path to transplant in the very young, and early transplant to cure could reduce disease-related morbidity.
- 23 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 994321
Open AccessChronic granulomatous disease and McLeod syndrome: Stem cell transplant and transfusion support in a 2-year-old patient—a case report
Chronic granulomatous disease (CGD) with McLeod neuroacanthocytosis syndrome (MLS) is a contiguous gene deletion disorder characterized by defective phagocytic function and decreased Kell antigen expression. CGD cure is achieved through hematopoietic stem cell transplant (HSCT) usually in the peri-pubescent years. The presence of MLS makes peri-transfusion support complex, however. Herein, we present the youngest known case of HSCT for CGD in the setting of MLS. A 2-year-old male patient was diagnosed with CGD plus MLS. Due to the severity of the child’s systemic fungal infection at diagnosis, HSCT was deemed the best treatment option despite his small size and age. A related, matched donor was available, and a unique red blood cell support plan had been implemented. Reduced-intensity conditioning was used to reduce the transplant-related mortality risk associated with myeloablative protocols. The transplant course was uneventful; autologous red blood cell (RBC) transfusion support was successful and allowed for the avoidance of possible antibody formation if allogeneic units had been used. The patient achieved 1-year relapse-free survival. The developed protocols provide a viable path to transplant in the very young, and early transplant to cure could reduce disease-related morbidity.
- 1 July 2021
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 35 (3) , 60-61
A Platelet Inventory Management Assessment: Is a Pathogen Reduced Only Inventory Financially Feasible?
- 1 July 2021
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 35 (3) , 60-61
A Platelet Inventory Management Assessment: Is a Pathogen Reduced Only Inventory Financially Feasible?